68 results about "Cystatin" patented technology

The invention relates to a preparation method of cystatin C antibody and a preparation method of a detection kit. Cystatin C (Cys C) is currently one of the most sensitive diagnostic markers for clinical kidney disease. The antibody preparation of the present invention is extracted and purified from human normal serum, and then a highly sensitive antigen is obtained by artificial modification. Animals were immunized multiple times to obtain hyperimmune serum containing Cys C antibody, and high-purity Cys C antibody was obtained by affinity chromatography. During the preparation process, the loss of antibody activity is small, and it is easy to produce in batches, and the antibody has high affinity and high titer, and does not generate cross-immune reaction. After the antibody is coupled with polystyrene latex balls, the prepared detection kit has higher sensitivity and linear range, good repeatability, low detection limit, easy automatic analysis, fast and simple operation. Due to the high purity of the antibody, the content of heteroantibody is very small, so there is less interference and the matrix is ​​stable.

Cystatin-based peptide tags, referred to here as inclusion body tags (IBTs), are disclosed useful for the generation of insoluble fusion peptides. The fusion peptides comprise at least one inclusion body tag operably linked to a peptide of interest. Expression of the fusion peptide in a host cell results in a product that is insoluble and contained within inclusion bodies in the cell and / or cell lysate. The inclusion bodies may then be purified and the protein of interest may be isolated after cleavage from the inclusion body tag.

Methods and compositions for modulating development and defense responses are provided. Nucleotide sequences encoding maize, soybean, wheat and rice cystatin proteins are provided. The sequences can be used in expression cassettes for modulating development, developmental pathways, and defense responses. Transformed plants, plant cells, tissues, and seed are also provided.

The invention discloses a recombinant human cystatin C gene and expression and application thereof. A truncated human cystatin C gene has a nucleic acid sequence as shown as in SEQ ID NO:1; the truncated human cystatin C protein has an amino acid sequence as shown in SEQ ID NO:2. The invention uses a genetic engineering technique to express and purify a great deal of stable recombinant soluble cystatin C protein and obtains a pair of monoclonal antibodies using the protein to prepare stable cystatin C diagnostic reagents and quality control products thereof, thereby solving bottleneck problems of independent research and development of a cystatin testing reagent box.

The invention belongs to the field of genetic engineering and medicines, and relates to a novel tumor marker for early diagnosis of colorectal cancer, in particular to a tumor marker related to the colorectal cancer and application thereof. The marker is a composition of CystatinSN (CST1), CystatinS (CST4) and CystatinSA (CST2). The marker as well as a primer and an antibody thereof can be applied to a diagnostic kit for the auxiliary diagnosis of the colorectal cancer.

In some embodiments, the present disclosure relates to an avian-free egg white composition comprising 45-63% Ovalbumin, 9-15% Ovotransferrin, 0-15% Ovomucoid, 3- 5% Ovoglobulin G2, 3-5% Ovoglobulin G3, 2.5-5% Ovomucin, 3-5% Lysozyme, 1-2% Ovoinhibitor, 0.8-1.5% Ovoglycoprotein, 0.6-1.0% Flavoprotein, 0.3-0.8% Ovomacroglobulin, 0.02-0.1% Avidin, and 0.02-0.1% Cystatin. In some embodiments, the composition comprises an edible yeast and one or more of the preceding proteins. In some embodiments, the avian-free egg white further comprises one or more of: flavor enhancers, calcium supplements, added vitamins, and a gelling agent. In some embodiments, the present disclosure pertains to a non-allergenic egg-white composition for human consumption. In some embodiments, the present disclosure pertains to methods of making the avian-free egg-white composition.

Cystatin-based peptide tags, referred to here as inclusion body tags (IBTs), are disclosed useful for the generation of insoluble fusion peptides. The fusion peptides comprise at least one inclusion body tag operably linked to a peptide of interest. Expression of the fusion peptide in a host cell results in a product that is insoluble and contained within inclusion bodies in the cell and / or cell lysate. The inclusion bodies may then be purified and the protein of interest may be isolated after cleavage from the inclusion body tag.

The present invention discloses the tumor invasion and metastasis resisting function and application of venin cysteine proteinase inhibitor, and belongs to the field of biomedicine. Through designing and synthesizing sv-Cystatin cDNA according to 99 amino acid sequences of Chinese cobra venin Cystatin protein, cloning to pPICZ alphaA vector and transforming Pichia yeast, stable and high expression engineering bacterium GS115-sv-Cystatin is screened out. Through further inducing expression and purification, the extracorporeal bioactivity experiment shows that the recombinant sv-Cystatin protein has the functions of inhibiting the activity of papain and inhibiting the tumor cell invasion and metastasis obviously, and so do the intracorporeal experiment. The present invention also constitutes pcDNA-sv-Cystatin eukaryotic expression vector. The present invention has huge application foreground in preventing and treating tumor.

The invention belongs to the field of genetic engineering and medicine, relates to a novel tumor marker for early diagnosis of pancreatic cancer, and more specifically discloses a new serum / tissue tumor marker associated with pancreatic cancer and application thereof. The marker is a combination of CystatinSN (CST1), CystatinS (CST4) and CystatinSA (CST2). The marker, primers and antibodies can be used for a diagnostic kit for the auxiliary diagnosis of pancreatic cancer.

Agents and natural and synthetic formulations and extracts are useful in control of pathogen infection and infestation in humans, animals and plants, as well as pathogen contamination in environmental locales. A method inhibits growth or infection or infestation of a pathogen, including contacting the pathogen with an effective amount of a combination of a plant defensin or a functional natural or synthetic derivative or variant thereof and a non-defensin peptide, such as a cathelicidin peptide, a hairpin peptide, a hairpin peptide from which disulfide bridges have been removed, indolicidin, synthetic peptide CP-29, or a peptide derived from a cystatin. The combination of the defensin and peptide are synergistic compared to the use of each alone at the same individual dose as used in the combination.

The invention provides a novel hydatidosis diagnosing antigen and an application thereof. Specifically, the invention provides echinococcus granulosus cystatin abbreviated to EgCystatin or genes of echinococcus granulosus or an application of a detection reagent of echinococcus granulosus. The EgCystatin, the genes of echinococcus granulosus and the detection reagent are used for preparing a positive antigen of echinococcus granulosus and / or used for preparing a reagent or a kit for diagnosing echinococcus granulosus. The antigen has very high diagnosis sensitivity and specificity to echinococcus granulosus and has the diagnostic efficiency higher than other conventional echinococcus granulosus antigens.

The invention discloses a tick cystatin. The tick cystatin is a Rhipicephalus haemaphysaloide cystatin Rhcyst-2. The invention also discloses a Rhipicephalus haemaphysaloide cystatin Rhcyst-2 gene. The Rhipicephalus haemaphysaloide cystatin Rhcyst-1 gene includes a nucleotide sequence coding an amino acid sequence represented by SEQ ID NO.1. The Rhipicephalus haemaphysaloide cystatin Rhcyst-2 has substantial cysteine protease inhibition activity and toxoplasma infection resistance, and is suitable for preparing anti-parasitical medicines.

A cystatin gene of meduse, its expression, and its use in suppressing the hydrolysis of protease are disclosed. The protein coded by said gene is a precursor protein composed of 131 amino acids, including the signal peptide containing 18 amino acid and the mature protein containing 113 amino acid. The purified recombinant protein has obvious suppression action on papain.

Skin quality is improved by orally administering a cystatin and / or a degraded product of cystatin in an amount of 10 μg / day or more per adult, or applying a composition that includes a cystatin and / or a degraded product of cystatin in an amount of 0.001 to 2 wt % based on a total amount of the composition.

The invention discloses a bufo melanostictus schneider cystatin and a gene of the bufo melanostictus schneider cystatin. The amino acid sequence of the bufo melanostictus schneider cystatin is shown as SEQ ID NO: 2, and the nucleotide sequence of the gene for coding the bufo melanostictus schneider cystatin is shown as SEQ ID NO: 1. The bufo melanostictus schneider cystatin obtained by means of prokaryotic expression has strong cathepsin-B inhibiting activity, is convenient to produce in vitro and can be used as a cathepsin-B inhibitor.

The invention discloses an application of CST1mRNA (Cystatin 1 Messenger RNA) and CST4mRNA (Cystatin 4 Messenger RNA) or proteins coded by CST1mRNA and CST4mRNA in preparation of bladder cancer markers and a kit thereof. When the CST1mRNA and the CST4mRNA or the proteins coded by the CST1mRNA and the CST4mRNA are combined and used for diagnosing and predicting bladder cancer, the specificity and sensitivity are higher than those of one marker therein. The invention further discloses the kit for detecting the markers. The kit is convenient in use, can be used for directly collecting urine for detecting without collecting serum so as to reduce the sampling pain of patients, has the characteristics of good specificity and high sensitivity, and can be used for bladder cancer diagnosis, curative effect assessment in the treatment process and metastasis recurrence monitoring after treatment so as to provide a guidance for advanced intervention of doctors.

The invention discloses a Chinese patent medicine for treating Type II diabetic nephropathy and a preparation method thereof. The Chinese patent medicine is prepared by the following raw materials in parts by weight: 15-35 parts of astragalus membranaceus, 10-15 parts of radix pseudostellariae, 12-15 parts of radix puerariae, 15-30 parts of semen coicis, 10-15 parts of radix rehmanniae, 12-15 parts of achyranthes root, 12-30 parts of serissa serissoide, 10-15 parts of winged euonymus twig, 12-15 parts of capparidaceae, 10-15 parts of rhizoma cyperi, 6-10 parts of rheum officinale, 6-10 parts of semen brassicae, and 2-6 parts of leech. The Chinese patent medicine for treating Type II diabetic nephropathy has effects of tonifying qi and yin, eliminating turbid fluid and dredging collaterals, and can be used for relieving the clinical symptoms of diabetic nephropathy patients, lowering fasting blood-glucose, creatinine and urea nitrogen, and improving the excretion rate of beta2-microglobulin and urine microalbumin, and the cystatin level, the total effective rate is 93.06%c, so that the Chinese patent medicine has reliable effect in treating diabetic nephropathy, has no obvious toxic and side effects, has high biological availability, and has good controllability and stability.

Cystatins that have been modified by glycosylation in order to enhance stability and activity are disclosed, as are methods of making such cystatins and methods of using such cystatins to inhibit proteolysis.

The invention provides a pseudosciaena crocea Cystatin recombinant protein and application thereof, and belongs to the technical field of gene engineering. The pichia pastoris engineering bacterium for efficiently expressing the pseudosciaena crocea Cystatin recombinant protein is constructed and is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO:M 2020369. The pseudosciaena crocea Cystatin recombinant protein produced by using pichia pastoris engineering bacteria can inhibit the activity of papain, pseudosciaena crocea cathepsin B and pseudosciaena crocea cathepsin S, up-regulate the expression level of inflammation-related factors TNF alpha in macrophages, and induce the generation of an antibacterial active substance nitric oxide in the macrophages; and therefore, the pseudosciaena crocea Cystatin recombinant protein has a good application prospect as a protease inhibitor and an immunopotentiator.

The invention discloses a lamprey oral gland CystatinF, a preparation method and application. The sequence similarity between the lamprey oral gland CystatinF (Lm-CystatinF) and reported snake poisonprotein cystatin is less than 29%, and the sequence similarity of the lamprey oral gland CystatinF (Lm-CystatinF) and other species are also very low (30%-40%), so that proliferation of human umbilical vein endothelial cells (HUVECs) is significantly restrained in a dose dependent mode, vascular endothelial cells are restrained from differentiating to be of a tubule structure, that is to say, thelamprey oral gland CystatinF (Lm-CystatinF) has anti-angiogenic activity. According to the lamprey oral gland CystatinF, the preparation method and application, the lamprey oral gland CystatinF is prepared through recombination from optimized lamprey oral gland CystatinF genes, the expression cycle is short, the expression rate is high, and obtained protein is soluble protein, so that enzyme digestion is not needed, one-step chromatography is achieved, and the method has the advantages of simple operation and high yield.

The invention discloses a tick cystatin. The tick cystatin is a Rhipicephalus haemaphysaloide cystatin Rhcyst-1. The invention also discloses a Rhipicephalus haemaphysaloide cystatin Rhcyst-1 gene. The Rhipicephalus haemaphysaloide cystatin Rhcyst-1 gene includes a nucleotide sequence coding an amino acid sequence represented by SEQ ID NO.1. The Rhipicephalus haemaphysaloide cystatin Rhcyst-1 has substantial cysteine protease inhibition activity and toxoplasma infection resistance, and is suitable for preparing anti-parasitical medicines.

The invention discloses an application of CST1mRNA (Cystatin 1 Messenger RNA) and CST4mRNA (Cystatin 4 Messenger RNA) or proteins coded by CST1mRNA and CST4mRNA in preparation of urethral carcinoma markers and a kit thereof. When the CST1mRNA and the CST4mRNA or the proteins coded by the CST1mRNA and the CST4mRNA are used for diagnosing and predicting urethral carcinoma, the specificity and sensitivity are higher than those of one marker therein. The invention further discloses the kit for detecting the markers. The kit is convenient in use, can be used for directly collecting urine for detecting without collecting serum so as to reduce the sampling pain of patients, has the characteristics of good specificity and high sensitivity, and can be used for urethral carcinoma diagnosis, curative effect assessment in the treatment process and metastasis recurrence monitoring after treatment so as to provide a guidance for advanced intervention of doctors.

The invention discloses a kit and a detection method of detecting latex-enhanced immune-nephelometry of cystatin C in serum or blood plasma. In the method, the cystatin C is measured in a manner of latex-enhanced immune projection nephelometry, wherein the cystatin C in a sample is subjected to a specific reaction with a latex particle-enhanced anti-cystatin C antibody to obtain an immune composition. The change of absorbancy of the immune composition under the wavelength of 546 nm is detected, wherein the change degree is in direct proportion to the content of the cystatin C in the sample, thereby obtaining the concentration of the target substance, cystatin C, in the sample. The kit of detection method of detecting latex-enhanced immune-nephelometry of cystatin C in serum or blood plasma of human body is composed of an R1 detection reagent, an R2 detection reagent and a Cys C calibration substance. The cystatin C is an ideal endogenous marker of measuring glomerular filtration rate (GFR) and is more sensitive and early-stage when compared with creatinine. The method is high in sensitivity and is high in clinical application value.

The invention discloses an antithrombotic polypeptide cystatin-T. The antithrombotic polypeptide cystatin-T is composed of 101 amino acid residues, has a molecular weight of 11,063.48 Da and an isoelectric point of 6.72, and has an amino acid sequence as shown in SEQ ID NO. 1 and a nucleic acid sequence as shown in SEQ ID NO. 2. The invention also discloses a preparation method and application ofthe above antithrombotic polypeptide cystatin-T. The antithrombotic polypeptide cystatin-T of the invention has the advantages of good stability, simple artificial expression, remarkable antithrombotic and cardio-cerebral vascular protection, and low hemolytic activity, and has a wide application prospect.

The invention relates to a fermented milk product includes angiogenin and / or angiogenin hydrolysate in an amount of 0.9 mg / 100 g to 150 mg / 100 g, and cystatin and / or cystatin hydrolysate in the mass ratio to the angiogenin and / or angiogenin hydrolysate of 0.006 to 1.7.